COULD A SINGLE DOSE OF THE DRUG IVERMECTIN STOP THE SARS-COV-2 VIRUS FROM GROWING
APRIL 13, 2020 @ 2.25PM
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint venture of the University of Melbourne and Royal Melbourne Hospital, has shown that an anti-parasitic drug already available around the world kills the SARS-CoV-2 virus within 48 hours.
The Monash Biomedicine Discovery Institute’s Dr Kylie Wagstaff, who led the study, said the scientists showed that the drug an, Ivermectin, stopped the SARS-CoV-2 virus growing in cell culture within 48 hours.
“We found that even a single dose could essentially remove all viral RNA by 48 hours and that even at 24 hours there was a really significant reduction in it,” Dr Wagstaff said. Ivermectin is an FDA-approved anti-parasitic drug that has also been shown to be effective in vitro against a broad range of viruses including HIV, Dengue, Influenza and Zika virus.
Dr Wagstaff cautioned that the tests conducted in the study were in vitro and that trials needed to be carried out in people.
Safe drug to be used
“Ivermectin is very widely used and seen as a safe drug. We need to figure out now whether the dosage you can use in humans will be effective – that’s the next step,” Dr Wagstaff said.
“In times when we’re having a global pandemic and there isn’t an approved treatment, if we had a compound that was already available around the world then that might help people sooner. Realistically it’s going to be a while before a vaccine is broadly available. Although the mechanism by which Ivermectin works on the virus is not known, it is likely, based on its action in other viruses, that it works to stop the virus ‘dampening down’ the host cells’ ability to clear it, Dr Wagstaff said.
Royal Melbourne Hospital’s Dr Leon Caly, a Senior Medical Scientist at the Victorian Infectious Diseases Reference Laboratory (VIDRL) at the Doherty Institute where the experiments with live coronavirus were conducted, is the study’s first author.
“As the virologist who was part of the team who were first to isolate and share SARS-COV2 outside of China in January 2020, I am excited about the prospect of Ivermectin being used as a potential drug against COVID-19,” Dr Caly said.
Ivermectin on different viruses
Dr Wagstaff made a previous breakthrough finding on Ivermectin in 2012 when she identified the drug and its antiviral activity with Monash Biomedicine Discovery Institute’s Professor David Jans, also an author on this paper. Professor Jans and his team have been researching Ivermectin for more than 10 years with different viruses.
Dr Wagstaff and Professor Jans started investigating whether it worked on the SARS-CoV-2 virus as soon as the pandemic was known to have started. The use of Ivermectin to combat COVID-19 would depend on the results of further pre-clinical testing and ultimately clinical trials, with funding urgently required to keep progressing the work, Dr Wagstaff said.
Drug repositioning, also known as drug repurposing, recycling, redirecting, re-tasking or reprofiling, has been gaining recognition as a new alternative approach that explores new avenues for the use of pre-existing commercially approved drugs to treat other diseases aside from its intended use in the original disease.
According to Prof Sunil K. Lal, Professor of Microbiology in School of Science at Monash University Malaysia, this approach has a myriad of advantages. “The biggest advantage especially in the case of Covid-19, is the ease of upscaling and speed for urgent administration into the field which can be expedited since safety and risk assessment studies on patients have already been conducted as part of the clearance process for the original application of the drug. Additionally, overall developmental expenses will be lower and clearances from the regulatory authorities can be easily expedited.”
He added “the greatest advantage of drug repositioning is that it gives new life to novel viral disease like COVID-19. Repositioning existing drugs such as hydroxychloroquine, nucleotide inhibitors, ledipasvir and now most recently Ivermectin for COVID-19 show great promise as new repositioned drugs.”
Read the full paper in Antiviral Research titled: The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.
The culture of colourism: The obsession with lighter skin tones driving opportunities in the skin lighteners market
SEE MORE: HEALTH A - Z
SEE MORE ON: PARENTING
SEE MORE ON: FITNESS
SEE MORE ON: NUTRITION
SEE MORE ON: AGEING
Digital Health Malaysia takes health transformation to new heights with fourth telemedicine conference
Astrazeneca signs MoA with InvestKL to improve access to healthcare, explore digital transformation in the management of diseases
SEE MORE ON: IN THE SPOTLIGHT
Roche launch Perjeta - Herceptin combination, a post surgery treatment for early breast cancer (eBC)
SEE MORE ON: PRODUCTS & SUPPLEMENTS
SEE MORE ON: MEN'S HEALTH
33% below 15 exposed to sexual intercourse, at higher risk of developing cervical cancer says oncologist
Breast cancer survivor emphasizes on monthly self-examination, says no alternative therapy, magic pill for cure
SEE MORE ON: WOMEN